tara-002
tara-002: developed by 1 company · 3 clinical trials tracked.
tara-002 evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
How could tara-002 → TARA affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Protara Therapeutics, Inc. (TARA) Lymphatic Malformation; Non-muscle Invasive Bladder Cancer; … | Phase 2 |
Clinical Trials (3)
A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-Grade Non-Muscle Invasive Bladder Cancer
Primary endpoint: Incidence of high-grade complete response
A Phase 2a/b Single Arm Open Label Study to Evaluate the Safety and Efficacy of Intracystic Administration of TARA-002 in Participants Between 6 Months to Less Than 18 Years of Age for the Treatment of Macrocystic and Mixed Cystic Lymphatic Malformations
Primary endpoint: Proportion of participants with clinical success after one treatment cycle of TARA-002
A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of Intravesical Instillation of TARA-002 in Adults With High-Grade Non-Muscle Invasive Bladder Cancer
Primary endpoint: Cohort A and B: Incidence of high-grade Complete Response at any time according to central pathology after treatment with TARA-002
Frequently asked questions
Who is developing tara-002?
tara-002 is being developed by Protara Therapeutics, Inc..
How many clinical trials involve tara-002?
BioSniper tracks 3 clinical trials involving tara-002.